| MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation Y Fang, L Wang, C Wan, Y Sun, K Van der Jeught, Z Zhou, T Dong, ... The Journal of clinical investigation 131 (1), 2021 | 82 | 2021 |
| Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer Y Liu, J Xu, HH Choi, C Han, Y Fang, Y Li, K Van der Jeught, H Xu, ... Nature communications 9 (1), 4718, 2018 | 61 | 2018 |
| An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity Z Zhou, K Van der Jeught, Y Fang, T Yu, Y Li, Z Ao, S Liu, L Zhang, ... Nature biomedical engineering 5 (11), 1320-1335, 2021 | 60 | 2021 |
| Arsenic trioxide induces cell cycle arrest and alters DNA methylation patterns of cell cycle regulatory genes in colorectal cancer cells H Eyvani, F Moghaddaskho, M Kabuli, A Zekri, M Momeny, ... Life Sciences 167, 67-77, 2016 | 38 | 2016 |
| Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells M Momeny, F Moghaddaskho, NK Gortany, H Yousefi, Z Sabourinejad, ... Scientific Reports 7 (1), 44075, 2017 | 37 | 2017 |
| ST2 as checkpoint target for colorectal cancer immunotherapy K Van der Jeught, Y Sun, Y Fang, Z Zhou, H Jiang, T Yu, J Yang, ... JCI insight 5 (9), 2020 | 36 | 2020 |
| Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells M Momeny, Z Sabourinejad, G Zarrinrad, F Moghaddaskho, H Eyvani, ... Scientific reports 7 (1), 45954, 2017 | 34 | 2017 |
| Blockade of nuclear factor-κB (NF-κB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells M Momeny, H Yousefi, H Eyvani, F Moghaddaskho, A Salehi, F Esmaeili, ... The international journal of biochemistry & cell biology 99, 1-9, 2018 | 33 | 2018 |
| Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells M Momeny, G Zarrinrad, F Moghaddaskho, A Poursheikhani, ... Scientific Reports 7 (1), 4204, 2017 | 33 | 2017 |
| Demethylation and alterations in the expression level of the cell cycle–related genes as possible mechanisms in arsenic trioxide–induced cell cycle arrest in human breast … F Moghaddaskho, H Eyvani, M Ghadami, J Tavakkoly-Bazzaz, ... Tumor Biology 39 (2), 1010428317692255, 2017 | 18 | 2017 |
| Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells M Momeny, Z Alishahi, H Eyvani, F Esmaeili, A Zaghal, P Ghaffari, ... Cellular Oncology 43, 81-93, 2020 | 16 | 2020 |
| Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells M Momeny, H Eyvani, F Barghi, SH Ghaffari, S Javadikooshesh, ... Anti-Cancer Drugs 29 (10), 1011-1020, 2018 | 12 | 2018 |
| Metabolic interventions: a new insight into the cancer immunotherapy T Yu, T Dong, H Eyvani, Y Fang, X Wang, X Zhang, X Lu Archives of biochemistry and biophysics 697, 108659, 2021 | 7 | 2021 |
| Targeting glutamine metabolism potentiates antigen presentation in colorectal cancer T Yu, K Van der Jeught, H Zhu, Z Zhou, S Sharma, S Liu, KM So, H Eyvani, ... Cancer Research 84 (6_Supplement), 6741-6741, 2024 | | 2024 |
| Author Correction: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity Z Zhou, K Van der Jeught, Y Fang, T Yu, Y Li, Z Ao, S Liu, L Zhang, ... Nature Biomedical Engineering, 1-1, 2023 | | 2023 |
| FARP1/RAC1/STAT3 Axis Circumvents CD8+ T Cell-Mediated Immunosurveillance by Restricting Antigen Presentation in Colorectal Cancer H Eyvani | | 2023 |
| Rho-GEF hampers CD8+T cells-mediated immunosurveillance by reducing antigen presentation H Eyvani, X Zhang Cancer Research 82 (12_Supplement), 1371-1371, 2022 | | 2022 |
| ST2 as checkpoint target for colorectal cancer immunotherapy" JCI insight, 2020 | | 2020 |
| ST2 as checkpoint target for colorectal cancer immunotherapy" | | 2020 |
| Anti-tumor activity of cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, in pancreatic ductal adenocarcinoma cells M Momeny, Z Alishahi, H Eyvani, S Hamzelou, SH Ghaffari Annals of Oncology 30, v786, 2019 | | 2019 |
